Joshua Arbesman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joshua Arbesman has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Ying Ni
Cancer Sciences, Cleveland Clinic Research, Cleveland Clinic, Cleveland, USA
36 shared publications - Pauline Funchain
Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA
27 shared publications - Brian Gastman
Department of Plastic Surgery Cleveland Clinic Cleveland Ohio USA
24 shared publications - Alan Shen
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio
23 shared publications - Brandon Bungo
Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
23 shared publications - C. Marcela Diaz-Montero
Cleveland Clinic 7 Cleveland, OH
23 shared publications
Latest Publications
- Open Access
- 15 September 2026
- Published by Elsevier in JAAD International
- Vol. 29, 41-42
CDKN2A c.146T>C (I49T) in Mexican-ancestry individuals: Findings from melanoma and population cohorts
- 15 September 2026
- Published by Elsevier in JAAD International
- Vol. 29, 41-42
Open AccessCDKN2A c.146T>C (I49T) in Mexican-ancestry individuals: Findings from melanoma and population cohorts
- 25 June 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (11) , 982-985
Evaluating Large Language Models for Melanocytic Lesion Pathology Report Interpretation
- 25 June 2026
- Published by Wiley in Journal of Cutaneous Pathology
- Vol. 53 (11) , 982-985
Evaluating Large Language Models for Melanocytic Lesion Pathology Report Interpretation
- Open Access
- 27 March 2026
- Published by Elsevier in SSRN Electronic Journal
Targeting Germline BRCA1-Associated Breast Cancer Through Transcriptome-Guided Immunoprevention
Women with germline BRCA1 variants face a high lifetime risk of breast cancer, underscoring the need for novel immunoprevention strategies. Although the BRCA1-mutant tumor microenvironment (TME) is recognized as immunologically active, the specific, targetable alterations that differentiate malignant tumors from BRCA1-mutant normal tissue within the same individual have not been clearly defined. We performed integrated transcriptomic and immunologic profiling on a unique cohort of trio BRCA1-mutant human breast tissues, including tumors, matched adjacent and distant normal tissues, and separate normal breast tissues from tumor-free BRCA1 carriers. This within-carrier design enables precise dissection of tumor-specific transcriptional and immune microenvironmental changes while controlling for both germline BRCA1 background and host immune context. Lead candidates were validated in a Brca1-deficient mouse model. Our analysis revealed a "hot but suppressed" TME, characterized by high CD8+ T-cell infiltration counteracted by PD-L1/CTLA4 upregulation. We uncovered that BRCA2 is upregulated in tumors, where its high expression paradoxically correlates with a "cold," T-cell-excluded immune phenotype. Concurrently, we identified an 80-gene "public" antigen signature, including lead candidates LEMD1, EPYC, H3C13, H3C14, and H4C15. Notably, these targets are most highly expressed in these "cold," high-BRCA2 tumors. The upregulation of Lemd1 was subsequently confirmed in the Brca1-deficient mouse model.These findings identify BRCA2 upregulation as a marker of an immunosuppressed state in BRCA1-mutant tumors. Our data highlight a targetable repertoire of shared antigens for the development of "off-the-shelf" preventive vaccines designed to overcome immune evasion in high-risk carriers.
- 27 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTargeting Germline BRCA1-Associated Breast Cancer Through Transcriptome-Guided Immunoprevention
Women with germline BRCA1 variants face a high lifetime risk of breast cancer, underscoring the need for novel immunoprevention strategies. Although the BRCA1-mutant tumor microenvironment (TME) is recognized as immunologically active, the specific, targetable alterations that differentiate malignant tumors from BRCA1-mutant normal tissue within the same individual have not been clearly defined. We performed integrated transcriptomic and immunologic profiling on a unique cohort of trio BRCA1-mutant human breast tissues, including tumors, matched adjacent and distant normal tissues, and separate normal breast tissues from tumor-free BRCA1 carriers. This within-carrier design enables precise dissection of tumor-specific transcriptional and immune microenvironmental changes while controlling for both germline BRCA1 background and host immune context. Lead candidates were validated in a Brca1-deficient mouse model. Our analysis revealed a "hot but suppressed" TME, characterized by high CD8+ T-cell infiltration counteracted by PD-L1/CTLA4 upregulation. We uncovered that BRCA2 is upregulated in tumors, where its high expression paradoxically correlates with a "cold," T-cell-excluded immune phenotype. Concurrently, we identified an 80-gene "public" antigen signature, including lead candidates LEMD1, EPYC, H3C13, H3C14, and H4C15. Notably, these targets are most highly expressed in these "cold," high-BRCA2 tumors. The upregulation of Lemd1 was subsequently confirmed in the Brca1-deficient mouse model.These findings identify BRCA2 upregulation as a marker of an immunosuppressed state in BRCA1-mutant tumors. Our data highlight a targetable repertoire of shared antigens for the development of "off-the-shelf" preventive vaccines designed to overcome immune evasion in high-risk carriers.
- 26 March 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (2) , e153-e155
Response to Alam et al., “Association between DPP4 inhibitor use and risk of skin cancer in type 2 diabetes: A real-world cohort study”
- 26 March 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (2) , e153-e155
Response to Alam et al., “Association between DPP4 inhibitor use and risk of skin cancer in type 2 diabetes: A real-world cohort study”
- Open Access
- 21 March 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (1) , 271-274
Antibiotics prior to immune checkpoint inhibitor therapy worsens survival in Merkel cell carcinoma: A TriNetX retrospective cohort study
- 21 March 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (1) , 271-274
Open AccessAntibiotics prior to immune checkpoint inhibitor therapy worsens survival in Merkel cell carcinoma: A TriNetX retrospective cohort study
- Open Access
Gene-Specific Cancer Patterns Among Pathogenic Germline Variant Carriers
Key Points: Question: What are the gene-specific cancer patterns and risks among carriers of pathogenic or likely pathogenic variants in cancer susceptibility genes in a population-based cohort? Findings: In this cohort study of 287,076 participants, carriers of pathogenic or likely pathogenic variants in cancer susceptibility genes had markedly higher cancer prevalence compared to noncarriers (e.g., 80% for MEN1 carriers vs 18.6%), with additional risk observed among monoallelic MUTYH co-carriers. Analyses also identified novel gene-cancer associations. Meaning: These findings highlight substantial heterogeneity in inherited cancer risk and support more individualized strategies for genetic testing, cancer screening, and risk assessment. Importance: We previously reported that >5% of the population carries pathogenic or likely pathogenic variants (P/LPVs) in key cancer susceptibility genes (CSGs). However, gene-specific cancer prevalence, spectrum, burden, lifetime risk, comorbidity, and the risk associated with autosomal recessive (AR) genes among carriers remain incompletely defined. Objective: To investigate cancer prevalence, spectrum, burden, lifetime risk, comorbidity, and the uncover novel associations between cancer susceptibility genes and cancer occurrence in a gene-specific manner. Design: A total of 72 cancer susceptibility genes was analyzed. Cancer diagnoses were identified using SNOMED codes and grouped into 35 categories. Setting: This study utilized short-read whole genome sequencing data and electronic health record (EHR) data from the All of Us controlled-tier database v8. Participants: A total of 287,076 participants with both genomic and EHR data were included in the analysis. Main Outcomes and Measures: The primary outcome was an occurrence of a P/LPV in key CSGs. The other outcome is the incidence of cancer diagnosis. Associations between P/LPVs and overall and site-specific cancer risk were evaluated using regression models adjusted for age, sex, race, and ethnicity. Results: Among genes with ≥10 unique carriers, cancer prevalence was highest for MEN1 (80%), followed by TP53 (57.7%), MLH1 (48.4%), and MSH2 (47.2%), compared to 18.6% among non-carriers. Carriers of P/LPVs in BRCA1, BRCA2, MLH1, APC, NF1, PTEN, and PALB2 had significantly earlier cancer diagnosis compared to non-carriers. Cancer prevalence was markedly higher in BRCA1 and BRCA2 carriers who are also mono-allelic MUTYH carriers (75% and 45.5%, respectively) compared with BRCA1 and BRCA2 alone (43.2% and 36.5%). Similar enrichment was observed for CHEK2 and PALB2 monoallelic MUTYH co-carriers. Adjusted survival analysis showed increased cancer risk for MLH1 (OR=6.08), PTEN (OR=5.80), and MSH2 (OR=5.19). Cancer specific analysis reveals significant novel associations including MITF with anal/perianal and prostate cancer; BLM with ovarian and soft tissue/sarcoma; WRN with gynecologic cancer (NOS); and FH with hematologic malignancy, alongside well-established gene-cancer relationships. Conclusions and Relevance: This population-based analysis defines gene-specific cancer prevalence, spectrum, and risk, including contributions from AR variants. These findings support more precise genetic testing, screening, and risk stratification for individuals carrying inherited P/LPVs.
Open AccessGene-Specific Cancer Patterns Among Pathogenic Germline Variant Carriers
Key Points: Question: What are the gene-specific cancer patterns and risks among carriers of pathogenic or likely pathogenic variants in cancer susceptibility genes in a population-based cohort? Findings: In this cohort study of 287,076 participants, carriers of pathogenic or likely pathogenic variants in cancer susceptibility genes had markedly higher cancer prevalence compared to noncarriers (e.g., 80% for MEN1 carriers vs 18.6%), with additional risk observed among monoallelic MUTYH co-carriers. Analyses also identified novel gene-cancer associations. Meaning: These findings highlight substantial heterogeneity in inherited cancer risk and support more individualized strategies for genetic testing, cancer screening, and risk assessment. Importance: We previously reported that >5% of the population carries pathogenic or likely pathogenic variants (P/LPVs) in key cancer susceptibility genes (CSGs). However, gene-specific cancer prevalence, spectrum, burden, lifetime risk, comorbidity, and the risk associated with autosomal recessive (AR) genes among carriers remain incompletely defined. Objective: To investigate cancer prevalence, spectrum, burden, lifetime risk, comorbidity, and the uncover novel associations between cancer susceptibility genes and cancer occurrence in a gene-specific manner. Design: A total of 72 cancer susceptibility genes was analyzed. Cancer diagnoses were identified using SNOMED codes and grouped into 35 categories. Setting: This study utilized short-read whole genome sequencing data and electronic health record (EHR) data from the All of Us controlled-tier database v8. Participants: A total of 287,076 participants with both genomic and EHR data were included in the analysis. Main Outcomes and Measures: The primary outcome was an occurrence of a P/LPV in key CSGs. The other outcome is the incidence of cancer diagnosis. Associations between P/LPVs and overall and site-specific cancer risk were evaluated using regression models adjusted for age, sex, race, and ethnicity. Results: Among genes with ≥10 unique carriers, cancer prevalence was highest for MEN1 (80%), followed by TP53 (57.7%), MLH1 (48.4%), and MSH2 (47.2%), compared to 18.6% among non-carriers. Carriers of P/LPVs in BRCA1, BRCA2, MLH1, APC, NF1, PTEN, and PALB2 had significantly earlier cancer diagnosis compared to non-carriers. Cancer prevalence was markedly higher in BRCA1 and BRCA2 carriers who are also mono-allelic MUTYH carriers (75% and 45.5%, respectively) compared with BRCA1 and BRCA2 alone (43.2% and 36.5%). Similar enrichment was observed for CHEK2 and PALB2 monoallelic MUTYH co-carriers. Adjusted survival analysis showed increased cancer risk for MLH1 (OR=6.08), PTEN (OR=5.80), and MSH2 (OR=5.19). Cancer specific analysis reveals significant novel associations including MITF with anal/perianal and prostate cancer; BLM with ovarian and soft tissue/sarcoma; WRN with gynecologic cancer (NOS); and FH with hematologic malignancy, alongside well-established gene-cancer relationships. Conclusions and Relevance: This population-based analysis defines gene-specific cancer prevalence, spectrum, and risk, including contributions from AR variants. These findings support more precise genetic testing, screening, and risk stratification for individuals carrying inherited P/LPVs.
- 17 January 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (5) , 1523-1525
Malpractice litigation in melanoma: Analysis of the LexisNexis Legal Database from 2000 to 2024
- 17 January 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 94 (5) , 1523-1525
Malpractice litigation in melanoma: Analysis of the LexisNexis Legal Database from 2000 to 2024
- Open Access
- 29 December 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 68, 191-198
Cutaneous melanocytic mosaicism with associated melanoma: A case series
- 29 December 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 68, 191-198
Open AccessCutaneous melanocytic mosaicism with associated melanoma: A case series